BPC-157 injection protocol, dosage chart, and reconstitution guide.
The complete guide to BPC-157 peptide injection — standard dosage protocols with a dosage chart by injury type, reconstitution math for both 5 mg and 10 mg vials, optimal injection sites relative to your injury, cycle length recommendations, half-life considerations, and what a physician-supervised BPC-157 dosage protocol looks like in clinical practice.
BPC-157 dosage chart
BPC-157 dosage varies by application, injury severity, and administration route. The following BPC-157 dosage chart reflects protocols used in clinical practice prior to the Category 2 restriction and is consistent with the dosing ranges used in published preclinical research scaled to human body weight.
| Application | Dosage per injection | Frequency | Route | Typical cycle length |
|---|---|---|---|---|
| Acute tendon/ligament injury | 250–500 mcg | 2x daily | Subcutaneous near injury | 4–8 weeks |
| Chronic tendinopathy | 500 mcg | 2x daily | Subcutaneous near injury | 8–12 weeks |
| Muscle tear / strain | 250–500 mcg | 1–2x daily | Subcutaneous near injury | 4–6 weeks |
| Joint inflammation | 250–500 mcg | 1–2x daily | Subcutaneous near joint | 6–10 weeks |
| Gut healing (IBS, leaky gut) | 250–500 mcg | 1–2x daily | Oral (capsule or sublingual) | 8–12 weeks |
| Post-surgical recovery | 250 mcg | 2x daily | Subcutaneous near surgical site | 4–8 weeks |
| General systemic / anti-inflammatory | 250 mcg | 1–2x daily | Subcutaneous (abdominal) | 6–8 weeks |
| BPC-157 + TB-500 stack | 250 mcg BPC + 750 mcg TB-500 | 1x daily each | Subcutaneous | 6–8 weeks |
BPC-157 half-life and dosing timing
The BPC-157 half-life is short — published pharmacokinetic data indicates a half-life of less than 30 minutes when administered intravenously or intramuscularly. Subcutaneous injection provides a slower absorption profile that extends effective tissue exposure, but the peptide is still cleared relatively quickly compared to longer-acting peptides like TB-500.
This short half-life of BPC-157 is the pharmacological rationale for twice-daily dosing in most protocols. Splitting the daily dose into a morning and evening injection maintains more consistent tissue exposure than a single daily injection. Some practitioners prescribe once-daily dosing for convenience with acceptable results, particularly at the 500 mcg dose level where peak tissue concentration is higher.
Reconstituting BPC-157: 5 mg and 10 mg vials
BPC-157 arrives from compounding pharmacies as lyophilized powder. Reconstitution with bacteriostatic water (BAC water) follows standard peptide preparation. Here is the math for both common vial sizes:
| Vial size | BAC water added | Concentration | 250 mcg dose = | 500 mcg dose = | Doses per vial |
|---|---|---|---|---|---|
| 5 mg | 1 mL | 5,000 mcg/mL | 5 units (0.05 mL) | 10 units (0.1 mL) | 10–20 |
| 5 mg | 2 mL | 2,500 mcg/mL | 10 units (0.1 mL) | 20 units (0.2 mL) | 10–20 |
| 10 mg | 2 mL | 5,000 mcg/mL | 5 units (0.05 mL) | 10 units (0.1 mL) | 20–40 |
| 10 mg | 3 mL | 3,333 mcg/mL | 7.5 units (0.075 mL) | 15 units (0.15 mL) | 20–40 |
When reconstituting BPC-157 10 mg vials, 2 mL of bacteriostatic water is the most common volume — it produces a convenient 5,000 mcg/mL concentration where each 10 units on an insulin syringe equals exactly 500 mcg. Always inject the BAC water slowly along the vial wall, never directly onto the powder. Roll gently until clear. Never shake. Store reconstituted BPC-157 refrigerated at 2–8°C and use within 28 days.
BPC-157 injection site strategy
BPC-157 peptide injection site selection is uniquely important compared to other peptides. BPC-157 appears to exert stronger local effects when injected subcutaneously near the target tissue. For a torn rotator cuff, inject in the shoulder area. For an Achilles tendon injury, inject near the ankle. For knee tendinopathy, inject in the tissue surrounding the knee. For general systemic applications or gut healing where local injection is not practical, standard abdominal subcutaneous injection is appropriate.
Rotate BPC-157 injection sites within the target area with each dose to prevent lipodystrophy. Use a 29-gauge or 30-gauge insulin syringe, pinch the skin, and inject at approximately 45 degrees into the subcutaneous fat layer. Post-injection, apply gentle pressure with an alcohol swab for 10 seconds.
BPC-157 cycle length
Standard BPC-157 cycle length is 4–8 weeks for acute injuries and 8–12 weeks for chronic conditions. Unlike growth hormone secretagogues, BPC-157 does not appear to cause significant receptor desensitization at standard doses. Some practitioners run continuous BPC-157 protocols for chronic gut healing conditions without cycling off. Most physicians recommend a 2–4 week break between cycles as a precautionary measure given the limited long-term human data available.
BPC-157 dosage protocol: putting it together
A typical BPC-157 dosage protocol for a moderate tendon injury looks like this: reconstitute a 5 mg vial with 2 mL BAC water, inject 250 mcg (10 units) subcutaneously near the injury site each morning and evening, continue for 6–8 weeks, then assess healing progress with your physician. If stacking with TB-500, add 750 mcg TB-500 once daily as a separate injection. Lab work is generally not required for BPC-157 protocols unless the patient has specific health conditions.
Not yet prescribable
BPC-157 is currently FDA Category 2, meaning compounding pharmacies cannot legally prepare it. These dosage protocols reflect clinical practice prior to the Category 2 restriction. Prescriptions may resume if FDA reclassifies BPC-157 to Category 1. No formal timeline has been published.